Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models

Science Translational Medicine, July 1, 2020

Improving Immunotherapy: A mesothelin-targeted immunotoxin enhances the anti-tumor activity of immune checkpoint inhibitor in patients with mesothelioma and in mice.

Lab/Branch/Program: 
Thoracic and GI Malignancies Branch
Citation: 

Q. Jiang, A. Ghafoor, I. Mian, D. Rathkey, A. Thomas, C. Alewine, M. Sengupta, M. A. Ahlman, J. Zhang, B. Morrow, S. M. Steinberg, I. Pastan, R. Hassan, Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Sci Transl Med 12, (550):eaaz7252 (2020).

Published Date: 
July, 2020